Related Experiment Videos
Nucleoside analogues for chronic hepatitis B
L M Wolters1, H G Niesters, R A de Man
1Department of Gastroenterology & Hepatology, University Hospital Rotterdam, The Netherlands.
European Journal of Gastroenterology & Hepatology
|December 14, 2001
Summary
Five nucleoside analogues inhibit hepatitis B virus replication by interfering with reverse transcription. However, potential cytotoxicity and viral resistance necessitate combination therapy for effective future treatment of this viral infection.
Area of Science:
- Virology
- Hepatology
- Pharmacology
Background:
- Hepatitis B virus (HBV) replication involves reverse transcription by viral polymerase within hepatocytes.
- Nucleoside/nucleotide analogues are a class of antiviral drugs targeting viral replication.
Purpose of the Study:
- To describe five nucleoside/nucleotide analogues that inhibit HBV replication.
- To discuss the implications of cytotoxicity and viral resistance to nucleoside analogue therapy.
Main Methods:
- Description of five nucleoside/nucleotide analogues.
- Analysis of antiviral activity in the context of cellular toxicity.
- Evaluation of potential for viral polymerase mutations leading to drug resistance.
Main Results:
- The described analogues interfere with HBV replication mechanisms.
- Cytotoxicity is a critical consideration when assessing antiviral efficacy.
- Prolonged therapy can lead to viral polymerase mutations, resulting in resistance and renewed replication.
Conclusions:
- Nucleoside analogues offer a strategy to inhibit HBV replication.
- Interpreting antiviral activity requires careful consideration of cellular toxicity.
- Combination therapy, potentially involving multiple nucleoside analogues or interferon, represents a promising future strategy against HBV.